MedTrace Logo

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

NCT00214058 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-11-19

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

Conditions

Interventions

DRUG

Carboplatin

DRUG

Docetaxel

Sponsors & Collaborators

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • David M Kushner, MD · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214058 on ClinicalTrials.gov